Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - Arvinas, Inc. reported a quarterly loss of $0.84 per share, which was better than the Zacks Consensus Estimate of a loss of $0.87, but worse than a loss of $0.49 per share a year ago, indicating an earnings surprise of +3.45% [1] - The company posted revenues of $22.4 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 53.28%, and a significant decline from year-ago revenues of $76.5 million [2] - Over the last four quarters, Arvinas has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Outlook - Arvinas shares have declined approximately 60.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.75 on revenues of $41.04 million, and for the current fiscal year, it is -$1.50 on revenues of $294.99 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Arvinas belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]